Macrogenics (MGNX) Stock Price, Quote & News

Company Profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic can...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 251 5172

Fax: 301 251 5321

Website: www.macrogenics.com

Address:

9704 Medical Center Drive, Rockville, United States

Budman10 Sep. 16 at 1:51 PM

$MGNX Positive HC Wainwright conference call/update this am. CEOsounds very excited to give the ESMO update.

1 · Reply

youspeaktome Sep. 15 at 6:00 PM

$MGNX @DLAT94 Agree. $MGNX is a little late to the B7-H3 party but the efficacy we've seen is amazing. B7-H3 is proving to be a great target. It's nice B7-H3 is broadly expressed in many cancers so $MGNX should be able to find a few niches to stand out in.

1 · Reply

DLAT94 Sep. 15 at 1:12 PM

$MGNX Interesting r/r here in light of the B7-H3 conjugates interest across BP. Daiichi/Merck, GSK and Roche pursuing SCLC, Biontech is going for Prostate and MGNX for SCCHN, Endometrial, Melanoma, Sarcoma.

1 · Reply

Q12021Dreaming Sep. 13 at 5:26 PM

$MGNX - take a look at the ties with the phase 3 trial of Taishan-302 success. Possible runner Monday AM.

1 · Reply

cautlooking Sep. 12 at 2:11 PM

$MGNX many shots on goal, excellent history of producing marketed drugs, strong balance sheet,2.3 billion in "bonus bucks" New CEO with a laser focus on creating shareholder value. overall a compelling investment opportunity.

0 · Reply

Budman10 Sep. 11 at 10:32 PM

$MGNX Nice volume coming in late the past week. Good sign.

0 · Reply

CatalystInvest Sep. 11 at 8:53 PM

$MGNX - Inexpensive ADC/TCE Biotech with Multiple Catalysts Ahead. Summary: — Positive risk/reward with MGNX trading at a discount to its $327 million cash position or $5.15/share. — Differentiated pipeline includes antibody drug conjugates (ADC), T-cell engagers (TCE), and lorigerlimab, with multiple near-term catalysts to drive potential upside. — Gilead’s recent activity on multiple TCEs & MGNX negative enterprise value suggest partnership is under appreciated & undervalued. — Upcoming data for MGC026 & lorigerlimab at ESMO 2026, MGC028 in late 2026, plus recent index inclusion could catalyze institutional interest. — Potential $2.4 billion in milestones plus royalties from Gilead, Sanofi, TerSera, and Incyte partnerships may add to MGNX's impressive $900 million in non-dilutive funding since 2021. https://seekingalpha.com/article/4944341-macrogenics-inexpensive-adctce-biotech-with-multiple-catalysts-ahead

0 · Reply

chole1 Sep. 9 at 3:17 PM

$MGNX as long as we can not avoid these low volume drops, we can not really move higher... waiting game continues

0 · Reply

Budman10 Sep. 3 at 11:25 PM

$MGNX what’s to come: ESMO 2026 presentations at the European Society for Medical Oncology taking place from October 23–27, 2026: MGC026 (B7-H3 ADC): Preliminary dose-escalation and tumor-specific cohort data will be presented. The company recently reported that the squamous cell carcinoma of the head and neck (SCCHN) cohort met its pre-specified response threshold to advance into Stage 2. Lorigerlimab (PD-1 × CTLA-4 bispecific DART molecule): Interim data from its Phase 2 LINNET study in advanced gynecologic cancers will be shared. MGC028 (ADAM9 ADC) Preliminary Results: MacroGenics expects to provide a clinical update with preliminary clinical data from its ongoing Phase 1 dose-escalation study in late 2026. MGC030 (Preclinical ADC) Study Commencement: After receiving expedited FDA clearance for its IND application earlier this year, MacroGenics plans to initiate its Phase 1 dose-escalation study for this first-in-class ADC in the current quarter (Q3 2026).

0 · Reply

PMD777 Sep. 2 at 10:03 PM

$MGNX hopefully the start

0 · Reply

MacroGenics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 9, 2026, 4:05 PM EDT - 7 days ago

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

2026-08-17T13:15:33.000Z - 4 weeks ago

MacroGenics price target raised to $11 from $9 at B. Riley

2026-08-16T14:06:53.000Z - 4 weeks ago

MacroGenics reports Q2 EPS 31c, consensus 26c

Aug 13, 2026, 4:05 PM EDT - 4 weeks ago

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

MacroGenics Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

MacroGenics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

MacroGenics Slides: Corporate presentation

Aug 11, 2026, 4:05 PM EDT - 5 weeks ago

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

2026-07-23T20:12:10.000Z - 7 weeks ago

MacroGenics provides update on MGC026 study

Jul 23, 2026, 4:01 PM EDT - 7 weeks ago

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

Jul 23, 2026, 8:00 AM EDT - 7 weeks ago

MacroGenics Slides: Corporate presentation

Jul 2, 2026, 9:25 AM EDT - 2 months ago

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

2026-06-22T20:45:10.000Z - 2 months ago

MacroGenics to receive $24.5M milestone payment from Sanofi

SNY

Jun 22, 2026, 4:43 PM EDT - 2 months ago

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

May 20, 2026, 10:30 AM EDT - 3 months ago

MacroGenics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 14, 2026, 4:01 PM EDT - 4 months ago

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

2026-05-13T20:39:44.000Z - 4 months ago

MacroGenics reports Q1 EPS (58c), consensus (55c)

May 13, 2026, 4:01 PM EDT - 4 months ago

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

May 13, 2026, 7:00 AM EDT - 4 months ago

MacroGenics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

MacroGenics Earnings release: Q1 2026

2026-05-11T22:48:03.000Z - 4 months ago

MacroGenics to sell GMP manufacturing operations to Bora for $122.5M upfront

2026-05-11T22:40:45.000Z - 4 months ago

MacroGenics trading resumes

May 11, 2026, 5:20 PM EDT - 4 months ago

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

2026-05-11T20:33:29.000Z - 4 months ago

MacroGenics trading halted, news pending

2026-05-04T11:49:28.000Z - 4 months ago

MacroGenics, Sagard enter expanded Zynyz royalty purchase agreement

INCY

May 4, 2026, 7:30 AM EDT - 4 months ago

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

Apr 22, 2026, 8:00 AM EDT - 4 months ago

MacroGenics Proxy statement: Proxy filing

2026-04-20T09:25:08.000Z - 4 months ago

MacroGenics price target raised to $6 from $4 at Barclays

2026-04-10T11:06:12.000Z - 5 months ago

MacroGenics upgraded to Buy at B. Riley after deal for Tubulus

GILD

2026-04-10T10:55:12.000Z - 5 months ago

MacroGenics upgraded to Buy from Neutral at B. Riley

2026-04-08T20:37:37.000Z - 5 months ago

MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study

Apr 8, 2026, 4:30 PM EDT - 5 months ago

FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study

Apr 8, 2026, 8:00 AM EDT - 5 months ago

MacroGenics Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 5 months ago

MacroGenics Proxy statement: Proxy filing

Mar 12, 2026, 10:00 AM EDT - 6 months ago

MacroGenics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 10:45 AM EDT - 6 months ago

MacroGenics Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:40 PM EDT - 6 months ago

MacroGenics Transcript: Leerink Global Healthcare Conference 2026

2026-03-10T09:15:35.000Z - 6 months ago

MacroGenics price target raised to $4 from $3 at Barclays

Mar 9, 2026, 4:01 PM EDT - 6 months ago

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

Mar 9, 2026, 7:00 AM EDT - 6 months ago

MacroGenics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 6 months ago

MacroGenics Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 6 months ago

MacroGenics Slides: Corporate presentation

Mar 3, 2026, 3:10 PM EST - 6 months ago

MacroGenics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 5:30 PM EST - 6 months ago

MacroGenics to Participate in Upcoming Investor Conferences

2026-02-23T23:20:15.000Z - 6 months ago

MacroGenics says FDA places partial clinical hold on Phase 2 LINNET study

Feb 23, 2026, 6:14 PM EST - 6 months ago

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

Dec 4, 2025, 7:55 AM EST - 9 months ago

MacroGenics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 4:05 PM EST - 9 months ago

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 4:00 PM EST - 10 months ago

MacroGenics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 6:00 PM EST - 10 months ago

MacroGenics Slides: Corporate Presentation

2025-11-12T21:23:19.000Z - 10 months ago

MacroGenics reports Q3 EPS 27c vs 90c last year

2025-11-12T21:22:50.000Z - 10 months ago

MacroGenics expects cash to fund operations into late 2027

Nov 12, 2025, 4:01 PM EST - 10 months ago

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Nov 12, 2025, 2:30 AM EST - 10 months ago

MacroGenics Earnings release: Q3 2025

Nov 12, 2025, 2:30 AM EST - 10 months ago

MacroGenics Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

2025-09-16T20:50:19.000Z - 1 year ago

MacroGenics assumed with an Overweight at Barclays

2025-09-16T20:20:17.000Z - 1 year ago

MacroGenics initiated with an Overweight at Barclays

Sep 8, 2025, 11:30 AM EDT - 1 year ago

MacroGenics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:30 PM EDT - 1 year ago

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:01 PM EDT - 1 year ago

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Aug 14, 2025, 7:00 AM EDT - 1 year ago

MacroGenics Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

MacroGenics Quarterly report: Q2 2025

Aug 13, 2025, 4:01 PM EDT - 1 year ago

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

Jun 10, 2025, 8:00 AM EDT - 1 year ago

MacroGenics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 7:00 AM EDT - 1 year ago

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

Jun 10, 2025, 7:00 AM EDT - 1 year ago

MacroGenics Slides: Corporate Presentation

Jun 3, 2025, 4:30 PM EDT - 1 year ago

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 13, 2025, 3:30 AM EDT - 1 year ago

MacroGenics Earnings release: Q1 2025

May 13, 2025, 3:30 AM EDT - 1 year ago

MacroGenics Quarterly report: Q1 2025

May 8, 2025, 10:30 AM EDT - 1 year ago

MacroGenics Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

MacroGenics Announces Date of First Quarter 2025 Financial Results

May 1, 2025, 4:30 PM EDT - 1 year ago

MacroGenics to Participate in Upcoming Investor Conference

Apr 11, 2025, 8:00 AM EDT - 1 year ago

MacroGenics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

MacroGenics Proxy statement: Proxy Filing

Mar 19, 2025, 4:30 PM EDT - 1 year ago

MacroGenics Earnings Call Transcript: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

MacroGenics Earnings release: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

MacroGenics Annual report: Q4 2024

Mar 12, 2025, 2:00 PM EDT - 1 year ago

MacroGenics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 11:20 AM EDT - 1 year ago

MacroGenics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 6, 2025, 7:30 AM EST - 1 year ago

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

Mar 5, 2025, 10:30 AM EST - 1 year ago

MacroGenics Transcript: TD Cowen 45th Annual Healthcare Conference

Dec 4, 2024, 7:30 AM EST - 1 year ago

MacroGenics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

MacroGenics Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:00 PM EST - 1 year ago

MacroGenics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 5, 2024, 4:01 PM EST - 1 year ago

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

Nov 5, 2024, 2:30 AM EST - 1 year ago

MacroGenics Earnings Call Transcript: Q3 2024

Nov 5, 2024, 2:30 AM EST - 1 year ago

MacroGenics Earnings release: Q3 2024

Nov 5, 2024, 2:30 AM EST - 1 year ago

MacroGenics Quarterly report: Q3 2024

Oct 30, 2024, 7:30 AM EDT - 1 year ago

MacroGenics Announces Leadership Transition

Oct 29, 2024, 4:30 PM EDT - 1 year ago

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Oct 25, 2024, 5:15 PM EDT - 1 year ago

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders

Oct 22, 2024, 7:30 AM EDT - 1 year ago

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

Budman10 Sep. 16 at 1:51 PM

$MGNX Positive HC Wainwright conference call/update this am. CEOsounds very excited to give the ESMO update.

1 · Reply

youspeaktome Sep. 15 at 6:00 PM

1 · Reply

DLAT94 Sep. 15 at 1:12 PM

1 · Reply

Q12021Dreaming Sep. 13 at 5:26 PM

$MGNX - take a look at the ties with the phase 3 trial of Taishan-302 success. Possible runner Monday AM.

1 · Reply

cautlooking Sep. 12 at 2:11 PM

0 · Reply

Budman10 Sep. 11 at 10:32 PM

$MGNX Nice volume coming in late the past week. Good sign.

0 · Reply

CatalystInvest Sep. 11 at 8:53 PM

0 · Reply

chole1 Sep. 9 at 3:17 PM

$MGNX as long as we can not avoid these low volume drops, we can not really move higher... waiting game continues

0 · Reply

Budman10 Sep. 3 at 11:25 PM

0 · Reply

PMD777 Sep. 2 at 10:03 PM

$MGNX hopefully the start

0 · Reply

chole1 Aug. 31 at 7:35 PM

$MGNX anoyne? kust month end? tx

2 · Reply

chole1 Aug. 31 at 7:25 PM

$MGNX they continue to short MGNX, and 4 seems be history without news / an update / insider buying?

0 · Reply

PMD777 Aug. 28 at 10:46 AM

$MGNX Come on turd - enough consolidation...let's rip while the market is hot.

1 · Reply

chole1 Aug. 24 at 6:51 PM

$MGNX I repeat myself... anyone that understands the XNCR +160% move into ESMO vs MGNX -11%? I am backing the wrong investment now for weeks and months...

0 · Reply

SumDay1Day Aug. 22 at 2:05 PM

$MGNX Keep your eyes on this. Looks like its priming up for a run. Im in, with a order for more on monday.

3 · Reply

chole1 Aug. 21 at 2:47 PM

$MGNX XNCR is on the way to be 10x MGNX market cap! no comment, just pure frustration

0 · Reply

Budman10 Aug. 19 at 11:40 PM

$MGNX Jeffries sold a few shares today, general council. These were sold under s a stock plan set up in April/may prior to any update on mg026 or Lori information that will be presented at ESMO. Preplanned for tax purposes.

1 · Reply

chole1 Aug. 18 at 2:12 PM

$MGNX goodbye 4s... terrible team, now half of management and BoD selling / announcing to sell shares!!

1 · Reply

youspeaktome Aug. 17 at 8:05 PM

$MGNX One more thing is the press release mentions "MacroGenics is advancing multiple preclinical programs that incorporate proprietary platforms for next-generation TCEs and ADCs. " We just saw Novartis buying Myricx Bio for $1.1 billion cash upfront just for their new ADC payloads that are preclinical. I hope Macrogenics is also working on new desperately needed payloads too for cancers developing resistance to MMAE and Topo payloads. That would be incredibly valuable to any big pharma............

0 · Reply

youspeaktome Aug. 17 at 5:38 PM

$MGNX I see this as 4 shots on goal MGC026 (B7-H3 ADC) MGC028 (ADAM9 ADC) MGC030 (undisclosed ADC entering into Phase 1 trials this quarter) MDG032 (undisclosed T-cell engager) in IND studies The first drug is a bit crowded but has a safety advantage. The last 3 drugs are wildcards but have little competition so are very valuable if they see good activity. They have cash through 2028 without any new partnerships so they have enough runway to see if any of the 4 drugs hit. IMO it'll take all 4 drugs completely failing to lose money on $MGNX when it's trading significantly below cash now

2 · Reply

johnnyutah007 Aug. 17 at 5:32 PM

$MGNX lower lows... going to 🎉 soon 👀

0 · Reply

anachartanalyst Aug. 17 at 5:02 PM

$MGNX https://anachart.com/wp-content/uploads/2026/08/1786986115_soc-img.jpg

0 · Reply

Market Cap	257.35M
Revenue (ttm)	149.50M
Net Income (ttm)	-74.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-49.91%
Debt to Equity Ratio	0.00

Volume	315,600
Avg Vol	604,886
Day's Range	N/A - N/A
Shares Out	63.70M
Stochastic %K	31%
Beta	1.22
Analysts	Sell
Price Target	$8.00